PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Conditions:   Solid Tumor, Adult;   Head and Neck Cancer;   Non Small Cell Lung Cancer;   Pancreatic Cancer;   Diffuse Large B Cell Lymphoma
Intervention:   Drug: CX-2029
Sponsor:   CytomX Therapeutics
Not yet recruiting

https://ift.tt/2swd3gU